

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number
WO 2004/090535 A1

(51) International Patent Classification⁷: **G01N 33/50**

(21) International Application Number:
PCT/GB2004/001495

(22) International Filing Date: **5 April 2004 (05.04.2004)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0307969.6 5 April 2003 (05.04.2003) GB

(71) Applicant (*for all designated States except US*): **THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW** [GB/GB]; Gilbert Scott Building, University Avenue, Glasgow Central Scotland G12 8QQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HODGINS, Malcolm, Briden** [GB/GB]; Section Squamous Cell Biology and Dermatology, Division of Cancer Sciences & Molecular Pathology, Robertson Building, University of Glasgow, Glasgow Central Scotland G12 8QQ (GB). **GREEN-HALGH, David** [GB/GB]; Section Squamous Cell Biology and Dermatology, Division of Cancer Sciences


& Molecular Pathology, Robertson Building, University of Glasgow, Glasgow Central Scotland G12 8QQ (GB). **EDWARD, Michael** [GB/GB]; Section Squamous Cell Biology and Dermatology, Division of Cancer Sciences & Molecular Pathology, Robertson Building, University of Glasgow, Glasgow Central Scotland G12 8QQ (GB). **REITH, Alison** [GB/GB]; Section Squamous Cell Biology and Dermatology, Division of Cancer Sciences & Molecular Pathology, Robertson Building, University of Glasgow, Glasgow Central Scotland G12 8QQ (GB).

(74) Agents: **FORREST, Graham et al.**; Mewburn Ellis LLP, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page.]

(54) Title: **MURINE LIVING TISSUE MODEL & USES THEREOF**



(57) Abstract: The invention provides an *in vitro* method for observing an effect of a test agent on a murine tumour model. The model consists a three-dimensional array of murine fibroblasts in a collagen gel which mimics a connective tissue substrate, on or in which are grown benign or malignant murine tumour cells. The model mimics the interactions between the tumour and the underlying tissue substrate, which in turn influence the effect which potential therapeutic or oncogenic agents have on the tumour tissue. Thus the models of the invention provide more physiologically relevant data than monolayer cultures or other available tissue models about the effects a particular test agent will have on tumour tissue *in vivo*. Preferred embodiments provide a model of epithelial tissue and tumours derived therefrom.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— with international search report